GI oncology practices—those managing colorectal cancer (CRC), gastric cancer, pancreatic adenocarcinoma, and other gastrointestinal malignancies—operate at the intersection of oncology's administrative intensity and gastroenterology's procedural complexity. The result is a workload that includes post-resection surveillance colonoscopy scheduling, tumor board case preparation, chemotherapy prior authorization, and molecular biomarker result tracking across multiple external laboratories. This is a volume of administrative coordination that most practices cannot manage well without dedicated support.
CRC Surveillance Colonoscopy: The Post-Treatment Recall Challenge
Patients who have undergone curative-intent resection for colorectal cancer require structured colonoscopy surveillance according to established timelines—typically at 1 year post-surgery, then at 3 years, then every 5 years if findings are negative. This recall schedule must be maintained across a growing panel of CRC survivors, each with their own surgical history and pathology findings influencing the surveillance interval.
According to the American Society of Clinical Oncology (ASCO), post-CRC surveillance adherence in community oncology settings falls below 50% in many practices—meaning a significant proportion of patients are not receiving timely colonoscopy, with implications for detecting recurrence or metachronous lesions at a curable stage. A virtual assistant managing the CRC surveillance recall list can systematically contact patients when they are due, coordinate scheduling with the GI suite, and document completion in the oncology care record.
Tumor Board Case Preparation
Multidisciplinary tumor board conferences are the central decision-making forum for GI oncology, where gastroenterologists, medical oncologists, surgical oncologists, radiation oncologists, radiologists, and pathologists review complex cases together. The administrative preparation for tumor board is substantial: assembling the case summary, pulling imaging studies and pathology reports, confirming that molecular testing results are available, and ensuring the case is loaded into the tumor board presentation system before the weekly conference.
A VA assigned to tumor board coordination can own this preparation workflow: receiving case nominations from physicians, pulling the required documents from the EMR and external sources, confirming case readiness with the presenting physician, and managing the conference roster and case log. This ensures that tumor board operates at its intended function rather than being derailed by missing documents or last-minute case additions.
Chemotherapy Prior Authorization
Chemotherapy prior authorization is among the most time-consuming authorization tasks in oncology. Regimens like FOLFOX, FOLFIRI, or FOLFIRINOX for colorectal or pancreatic cancer require documentation of pathology staging, molecular markers (KRAS, NRAS, BRAF, MSI status), prior treatment lines, and ECOG performance status. Commercial payers frequently require multi-step submissions, peer-to-peer calls for complex regimens, and renewal authorizations every 90 days.
VAs trained in oncology authorization workflows can manage the submission pipeline: building the clinical justification packet, submitting to payer portals, tracking status, scheduling peer-to-peer calls, and filing appeals when authorizations are denied or delayed. For GI oncology practices managing multiple active chemotherapy patients simultaneously, this represents a significant administrative burden that cannot be responsibly assigned to clinical staff as an add-on task.
Molecular Testing Result Tracking
Comprehensive molecular profiling—including next-generation sequencing (NGS) panels, MSI/MMR testing, and liquid biopsy—is now standard in advanced GI oncology. Results arrive from external laboratories (Foundation Medicine, Guardant Health, Tempus) on varying timelines and must be matched to the correct patient, reviewed for reportable findings, and routed to the treating oncologist before the next clinical decision point.
VAs can maintain a molecular testing tracker: logging test orders, monitoring expected result windows, flagging overdue reports, and documenting result receipt in the EMR. When results with actionable findings arrive, VAs can alert the oncology team immediately rather than allowing reports to sit in an inbox during a high-volume clinic day.
The Case for GI Oncology-Specific VA Support
GI oncology practices that invest in VA support for administrative coordination are not just reducing staff burden—they are building the infrastructure to treat more patients, maintain tighter surveillance protocols, and avoid the authorization delays that interrupt treatment timelines. Stealth Agents works with oncology and GI specialty practices to identify virtual assistants with the clinical knowledge and coordination experience to manage these demanding workflows.
Sources
- American Society of Clinical Oncology (ASCO). Post-Treatment Surveillance in CRC Survivors, 2023.
- National Comprehensive Cancer Network (NCCN). Colon Cancer Clinical Practice Guidelines v2.2025.
- Robson ME, et al. "Prior Authorization Barriers to Timely Cancer Treatment." Journal of Clinical Oncology, 2024.
- Foundation Medicine. Molecular Profiling in GI Oncology: Clinical Utility Report, 2024.